Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Apollo Hospitals Enterprise Limited (508869) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Apollo Hospitals Enterprise Limited ₹2,073, price ₹8,116, upside -74.5%, quality 54 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
AH
Thin data
Sep 24, 2026
Apollo Hospitals Enterprise Limited
508869 · BSEStretched ValuationStrong overvaluation with only moderate quality.
!Fair value ₹2,073 · Strongly overvalued (−74.5%)
!Quality 54/100
!Expensive Growth (revenue 5y +14.1 %/yr)
!Thin margins · 1.5% net margin (TTM)
!Moderate debt
✓0.3% dividend yield · Well covered
!Narrow moat 34/100
!Evidence only low, so the estimate is less certain
Watch Apollo Hospitals Enterprise Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹3,104 – ₹9,060 · fair‑value band ₹849.54 – ₹2,989 · the ₹8,116 price screens above the ₹2,073 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India and internationally. The company's healthcare facilities comprise primary, secondary, and tertiary care facilities.
Show more
Apollo Hospitals Enterprise Limited, together with its subsidiaries, provides healthcare services in India and internationally. The company's healthcare facilities comprise primary, secondary, and tertiary care facilities. Its tertiary care hospitals provide care in approximately 55 specialties, including cardiac sciences, oncology, critical care, neurosciences, orthopedics, gastroenterology, and transplants. The company also provides other services, such as project consultancy, health insurance, and research services. In addition, it operates pharmacies, primary care clinics, birthing centers, specialized birthing centers, single specialty clinics, primary health centers and diagnostic chains, dental clinics, and daycare and home healthcare centers. The company's footprint includes 10,167 beds, 3,428 pharmacies, and 765 retail healthcare centers. Apollo Hospitals Enterprise Limited was founded in 1979 and is based in Chennai, India.
Stock analysis
Apollo Hospitals Enterprise Limited (508869) currently trades at ₹8,116, while our model-based Fair Value estimate is ₹2,073, 74.5% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹2,430 per share, and 0 of the 26 models we run sit above the ₹8,116 price.
Bear case: the Dividend Discount group reads lowest at ₹296.99, and 26 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹849.54 (bear) to ₹2,989 (bull), the price of ₹8,116 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Apollo Hospitals Enterprise Limited reported revenue of ₹218B in FY2025 versus ₹106B in FY2021, a compound +19.9%/yr. Reported net income was ₹14.5B in FY2025, compounding +76.1%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap ₹308B (≈ $3.2B) · P/E ratio 193.0 · P/S ratio 12.8 · EPS (TTM) ₹11.75 · Dividend yield 0.3% · Net margin 6.6% · Return on equity 4.1% · Return on assets (EBIT) 10.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 10% below its 52-week high and 20% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at −74%, 508869 screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely (₹296.99 to ₹3,963). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear ₹849.54
Fair Value ₹2,073
Bull ₹2,989
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹5.75 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EPV
₹1,056
₹1,267
₹1,450
74
Residual Income
₹655.94
₹898.51
₹1,557
73
5Y EBITDA Exit
₹1,317
₹3,095
₹5,475
71
All 26 models by family
DCF Models
FCF DCF
₹119.95
₹462.56
₹1,191
69
Owner Earnings
₹183.77
₹624.74
₹1,424
69
5Y Revenue Exit
₹870.68
₹2,119
₹3,929
68
5Y EBITDA Exit
₹1,317
₹3,095
₹5,475
71
5Y P/E Exit
₹946.82
₹2,285
₹3,919
67
10Y Revenue Exit
₹562.81
₹1,662
₹3,570
60
10Y EBITDA Exit
₹912.16
₹2,386
₹4,911
63
10Y P/E Exit
₹665.90
₹1,785
₹3,561
59
Earnings-Based
Graham-Dodd
₹706.71
₹3,963
₹5,505
63
Lynch FV
₹1,109
₹1,585
₹2,060
61
PEG = 1.0
₹1,109
₹1,585
₹2,060
57
EPV
₹1,056
₹1,267
₹1,450
74
Dividend Discount
Gordon GGM
₹172.46
₹343.65
₹520.38
67
DDM Multi-Stage
₹172.46
₹296.99
₹362.74
67
Multiples
P/E Multiple
₹1,715
₹2,286
₹2,858
63
P/S Multiple
₹1,325
₹1,767
₹2,208
58
P/B Multiple
₹1,325
₹1,767
₹2,208
55
EV/EBIT
₹1,803
₹2,499
₹3,195
66
EV/EBITDA
₹2,007
₹2,770
₹3,534
67
EV/Revenue
₹1,206
₹1,844
₹2,483
53
Asset-Based
NCAV (Graham)
₹295.14
₹395.49
₹590.28
54
Growth DCF
Growth DCF
₹109.67
₹473.76
₹1,016
70
Rev-Margin DCF
₹870.68
₹2,048
₹3,670
68
Economic Profit
Residual Income
₹655.94
₹898.51
₹1,557
73
ROIC Compounder
₹1,272
₹1,897
₹2,764
70
Growth Earnings
Growth-Adj P/E
₹1,701
₹2,430
₹3,159
67
Notify me when 508869 reaches fair value
Put 508869 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
54/100
Of which business quality 56 · Market factors (momentum, volatility) 61
Profitability
64
Margins and returns on capital today
Quality Growth
46
Are margins and returns improving?
Cashflow
36
Earnings quality: real cash, not paper profit
Fin. Strength
66
Balance sheet, leverage, solvency risk
Investment
40
Disciplined investing over empire-building
Low Volatility
95
Calm price path (market factor)
Momentum
45
Price trend over the last 3–12 months (market factor)
52W Momentum
49
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.1%
Start year 2020 (pandemic). Over 10 years: +15.5% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.7%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +26.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+26.6%
Dividend (yield on the price)0.3%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 11%
⚠ Rate on operating basis: 2025 sits 61% above its own trend.
508869 screens overvalued: fair value 74% below the price. Compare with KMCSHIL →
Compare Apollo Hospitals Enterprise Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Hospitals” was too small, so the broader sector is used.)Health Care · 2433 stocks
Beats the sector median on 3/13 measures
Overall it trails its sector peers.
Valuation Multiplesvs Health Care median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Hospitals stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| KMCSHIL KMCSHIL | ₹171.95 | ₹114.62 | −33% |
| 516110 516110 | ₹1.76 | ₹0.3300 | −81% |
| Eli Lilly and Company LLY | $1,157 | $749.08 | −35% |
| Johnson & Johnson, JNJ | $264.74 | $168.85 | −36% |
| AbbVie Inc ABBV | $261.59 | $259.62 | −1% |
| Roche Holding RO | CHF 375.20 | CHF 326.56 | −13% |
| Merck & Co MRK | $143.81 | $129.26 | −10% |
| UnitedHealth Group UNH | $367.08 | $295.49 | −20% |
| Novartis AG NOVN | CHF 118.06 | CHF 121.90 | +3% |
| Thermo Fisher Scientific Inc TMO | $675.05 | $686.04 | +2% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Apollo Hospitals Enterprise Limited (508869) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹2,073 versus a price of ₹8,116, about −74% upside (overvalued).
What is the fair value of 508869?
Our model-based fair value for Apollo Hospitals Enterprise Limited is ₹2,073 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹8,116.
What is the quality score of 508869?
Apollo Hospitals Enterprise Limited has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Apollo Hospitals Enterprise Limited (508869)?
Our model-based price target is the fair value of ₹2,073 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ₹849.54, optimistic scenario ₹2,989. It is a calculation from audited fundamentals, not an analyst target.
What is the Apollo Hospitals Enterprise Limited stock forecast for 2026?
Our models put fair value at ₹2,073, about −74% upside versus a price of ₹8,116 (overvalued). Cautious scenario ₹849.54, optimistic scenario ₹2,989. The calculation is refreshed regularly with new filings.
What is the revenue of Apollo Hospitals Enterprise Limited (508869)?
Apollo Hospitals Enterprise Limited reported trailing-twelve-month revenue of about ₹108B (latest available figure, as of Sep 24, 2026).
Does Apollo Hospitals Enterprise Limited pay a dividend?
Apollo Hospitals Enterprise Limited currently shows a dividend yield of about 0.26% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Apollo Hospitals Enterprise Limited (508869)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Apollo Hospitals Enterprise Limited it is ₹2,073 per share (as of Sep 24, 2026), against a price of ₹8,116. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Apollo Hospitals Enterprise Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 508869 trades above its calculated fair value: price ₹8,116, fair value ₹2,073, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 508869?
No. The price is what the market pays today (₹8,116); the fair value is what the company's own numbers justify (₹2,073). For Apollo Hospitals Enterprise Limited the two are ₹6,043 per share apart. That gap is exactly why we show both numbers side by side.
How much is Apollo Hospitals Enterprise Limited worth?
The market values Apollo Hospitals Enterprise Limited at about ₹308B (market capitalisation, as of Sep 24, 2026). Per share that is ₹8,116; our models calculate a fair value of ₹2,073 per share.
What do the bullish and bearish scenarios say about 508869?
Our models span a range for Apollo Hospitals Enterprise Limited: cautious scenario ₹849.54, base ₹2,073, optimistic ₹2,989 per share (as of Sep 24, 2026, price ₹8,116). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 508869?
Apollo Hospitals Enterprise Limited trades at a price-to-earnings ratio of 193.0 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹2,073 is built from several models across several years. Other multiples: P/B 3.8, P/S 2.9, EV/EBITDA 37.7.
How solid is the balance sheet of Apollo Hospitals Enterprise Limited (508869)?
Balance-sheet figures for Apollo Hospitals Enterprise Limited (as of Sep 24, 2026): return on equity 4.1%, debt of 0.54 per unit of equity. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is 508869 from its 52-week high?
Apollo Hospitals Enterprise Limited trades at ₹8,116, about 10% below its 52-week high of ₹9,060 and 20% above the low of ₹6,778 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹2,073 is for.
Which stocks are comparable to Apollo Hospitals Enterprise Limited?
From the same area (Healthcare) we also value KMCSHIL, 516110, Eli Lilly and Company, Johnson & Johnson,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Apollo Hospitals Enterprise Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹8,116, calculated fair value ₹2,073 (−74%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 508869 calculated?
We run Apollo Hospitals Enterprise Limited through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹2,073, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Apollo Hospitals Enterprise Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Apollo Hospitals Enterprise Limited (508869)?
The closing price on Oct 1, 2026 was ₹8,116. Our model-based fair value is ₹2,073, about −74% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Apollo Hospitals Enterprise Limited right now?
The price sits above even our optimistic bull case (₹2,989). The favourable scenario is already priced in. The model range is unusually wide (₹849.54 to ₹2,989). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Apollo Hospitals Enterprise Limited
How large is the market capitalisation of Apollo Hospitals Enterprise Limited (508869)?
The market capitalisation of Apollo Hospitals Enterprise Limited is ₹308B (≈ $3.2B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Apollo Hospitals Enterprise Limited (508869)?
The price-to-sales ratio of Apollo Hospitals Enterprise Limited is 12.8 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Apollo Hospitals Enterprise Limited (508869)?
Earnings per share at Apollo Hospitals Enterprise Limited are ₹11.75 (price ÷ EPS = P/E 193.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Apollo Hospitals Enterprise Limited (508869)?
The dividend yield of Apollo Hospitals Enterprise Limited is 0.3% (payout 180%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Apollo Hospitals Enterprise Limited (508869)?
The net margin of Apollo Hospitals Enterprise Limited is 6.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Apollo Hospitals Enterprise Limited (508869)?
The return on equity (ROE) of Apollo Hospitals Enterprise Limited is 4.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Apollo Hospitals Enterprise Limited (508869)?
On an EBIT basis the return on assets of Apollo Hospitals Enterprise Limited is 10.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Apollo Hospitals Enterprise Limited (508869)?
The operating margin of Apollo Hospitals Enterprise Limited is 4.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Apollo Hospitals Enterprise Limited (508869)?
Revenue at Apollo Hospitals Enterprise Limited is growing −2.8% versus a year earlier (3y avg +14.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Apollo Hospitals Enterprise Limited (508869)?
Earnings per share at Apollo Hospitals Enterprise Limited are growing −30.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Apollo Hospitals Enterprise Limited in the live analysis
One click puts Apollo Hospitals Enterprise Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.